Intracranial anaplastic meningioma is a malignant type of meningioma with a high rate of recurrence and death. Given its rarity, minimal information regarding this tumour is available. Thus, we studied a series of patients with anaplastic meningiomas and analysed the survival rates, prognostic factors...
As exemplified in Figure 2 for tumour MBT-1, the malignant brain tumours of patients III-1(MBT-1), III-3 (MBT-3), and III-4 (MBT-4, MBT-4R) and the myoepithelioma of patient III-1 (My-1), but not his meningioma (M-1), showed loss of the wild-type G-allele and retention...
As exemplified in Figure 2 for tumour MBT-1, the malignant brain tumours of patients III-1(MBT-1), III-3 (MBT-3), and III-4 (MBT-4, MBT-4R) and the myoepithelioma of patient III-1 (My-1), but not his meningioma (M-1), showed loss of the wild-type G-allele and retention...
Thus, a caveat remains for atypical meningioma patients diagnosed before 2005. In 2009, Boskos et al (2009) published cause-specific survival data on 19 atypical meningioma patients and found a 5-year survival rate of 80%, which is well in line with the present rate. On the basis of a ...
Postmastectomy radiotherapy (PMRT), as an important regional treatment, improves the survival rate of patients with T3N0M0 breast cancers. However, the therapeutic effect of PMRT on T3N0M0 patients in different age groups is unclear. Methods Using Surveillance, Epidemiology, and End Results data...
Hodgkin, Hodgkin lymphoma; HP, hypothalamic–pituitary; LCH, Langerhans cell histiocytosis; LGG, low-grade glioma; non-Hodgkin, non-Hodgkin lymphoma; NRSTS, nonrhabdomyosarcoma soft tissue sarcoma; QoL, quality of life; RMS, rhabdomyosarcoma; SMN, subsequent malignant neoplasm (including meningioma)....
Primary outcome: treatment persistence rate; secondary outcomes: colectomy-free survival and treatment switching. Funding: None disclosed. Key results At 12 months following treatment initiation, the persistence rates were 64.6% for adalimumab and 64.4% for golimumab (P=.681). Overall, 37 (20.2%) ...
The median overall survival (OS) has passed 19 months, and the 19-month survival rate in the olaptesed pegol, bevacizumab, and radiotherapy cohort is 10 times greater than a matched reference cohort receiving the standard of care (50% vs 5%, respectively). “The survival data in the cohort...
Between 1953 and 1980, a total of 935 patients underwent surgery for intracranial meningioma in the Department of Neurosurgery of the Helsinki University H... K Merja,S Risto,H Timo,... - 《Neurosurgery》 被引量: 466发表: 1992年 Long-term immunological investigation of malignant intracranial ...
Combining olaptesed pegol with bevacizumab and radiotherapy showed a 10-fold improvement in survival rate compared with the standard-of-care among patients with glioblastoma. Human brain © Sergey Nivens - stock.adobe.com Olaptesed pegol (NOX-A12), a CXCL12 inhibitor, plus the VEGF inhibitor ...